EDP Sciences logo
rechercher
Menu
Accueil Tous les numéros Numéro 19 (Juin 2019) Cah. Myol., 19 (2019) 49-56 References
Open Access
Issue
Cah. Myol.
Number 19, Juin 2019
Page(s) 49 - 56
Section Journée Pompe 2019 / Pompe Disease Day 2019
DOI https://doi.org/10.1051/myolog/201919020
Published online 5 juillet 2019
  1. Elenga N, Verloes A, Mrsic Y, et al., Incidence of infantile Pompe disease in the Maroon population of French Guiana. BMJ Paediatr Open. 2018 ; 2 : e000182. [CrossRef] [PubMed] [Google Scholar]
  2. Papadimas GK, Spengos K, Konstantinopoulou A, et al., Adult Pompe disease: clinical manifestations and outcome of the first Greek patients receiving enzyme replacement therapy. Clin Neurol Neurosurg. 2011 ; 113 : 303–7. [CrossRef] [PubMed] [Google Scholar]
  3. Terzis G, Dimopoulos F, Papadimas GK, et al., Effect of aerobic and resistance exercise training on late-onset Pompe disease patients receiving enzyme replacement therapy. Mol Genet Metab. 2011 ; 104 : 279–83. [Google Scholar]
  4. Terzis G, Krase A, Papadimas G, et al., Effects of exercise training during infusion on late-onset Pompe disease patients receiving enzyme replacement therapy. Mol Genet Metab. 2012 ; 107 : 669–73. [Google Scholar]
  5. Papadimas GK, Terzis G, Methenitis S, et al., Body composition analysis in late-onset Pompe disease. Mol Genet Metab. 2011 ; 102 : 41–3. [Google Scholar]
  6. Semplicini C, Letard P, De Antonio M, et al., Late-onset Pompe disease in France: molecular features and epidemiology from a nationwide study. J Inherit Metab Dis. 2018 ; 41 : 937–46. [CrossRef] [PubMed] [Google Scholar]
  7. van der Beek NA, Hagemans ML, van der Ploeg AT, et al., The Rasch-built Pompe-specific activity (R-PAct) scale. Neuromuscul Disord. 2013 ; 23 : 256–64. [CrossRef] [PubMed] [Google Scholar]
  8. Scheidegger O, Leupold D, Sauter R, et al., 36-Months follow-up assessment after cessation and resuming of enzyme replacement therapy in late onset Pompe disease: data from the Swiss Pompe registry. J Neurol. 2018 ;265 : 2783–8. [CrossRef] [PubMed] [Google Scholar]
  9. Stepien KM, Hendriksz CJ, Roberts M, et al., Observational clinical study of 22 adult-onset Pompe disease patients undergoing enzyme replacement therapy over 5years. Mol Genet Metab. 2016 ; 117 : 413–8. [Google Scholar]
  10. Lagalice L, Pichon J, Gougeon E, et al., Satellite cells fail to contribute to muscle repair but are functional in Pompe disease (glycogenosis type II). Acta Neuropathol Commun. 2018 ; 6 : 116. [Google Scholar]
  11. Slingerland NW, Polling JR, van Gelder CM, van der Ploeg AT, Bleyen I, Ptosis, extraocular motility disorder, and myopia as features of Pompe disease. Orbit. 2011 ; 30 : 111–3. [CrossRef] [PubMed] [Google Scholar]
  12. Ravaglia S, Bini P, Garaghani KS, Danesino C, Ptosis in Pompe disease: common genetic background in infantile and adult series. J Neuroophthalmol. 2010 ; 30 : 389–90. [Google Scholar]
  13. Yanovitch TL, Banugaria SG, Proia AD, Kishnani PS, Clinical and histologic ocular findings in Pompe disease. J Pediatr Ophthalmol Strabismus. 2010 ; 47 : 34–40. [PubMed] [Google Scholar]
  14. Toussaint D, Danis P, Ocular histopathology in generalized glycogenosis (Pompe’s disease). Arch Ophthalmol. 1965 ; 73 : 342–9. [CrossRef] [PubMed] [Google Scholar]
  15. Armour SM, Nordin J, Puzzo F, et al., Safety and efficacy evaluation of investigational liver gene transfer for secretable GAA in the treatment of Pompe disease. Mol Genet Metab. 2019 ; 126 : S24. [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.